Drug Trial Radar · NCT02556736
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Dec 14, 2015
Primary completion
Jun 1, 2020
Study completion Oct 21, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
Conditions
- Advanced Retinitis Pigmentosa
Interventions
AGN-151597Drug
AGN-151597 is a gene therapeutic delivered by intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to AGN-151597Time frame: Baseline (Day 1) to 6 Months
- Visual Acuity in the Study Eye at Baseline and Month 6Time frame: Baseline (Day 1), 6 Months
- Change From Baseline at Month 6 in Full Field Sensitivity in the Study Eye - Blue Light ThresholdTime frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in Full Field Sensitivity in the Study Eye - Red Light ThresholdTime frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in Full Field Sensitivity in the Study Eye - White Light ThresholdTime frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in Ambulation in the Study Eye (Time)Time frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in Ambulation in the Study Eye (Distance)Time frame: Baseline (Day 1) to Month 6
- Intraocular Pressure (IOP) Measurements in the Study EyeTime frame: Baseline (Day 1), 6 Months
- Anatomical Parameters as Measured in the Study Eye by Color Fundus Photography and AutofluorescenceTime frame: Baseline (Day 1), 6 Months
- Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Retinal Nerve Fibre Layer VolumeTime frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Ganglion Cell and Inner Plexiform Layer VolumeTime frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Retinal VolumeTime frame: Baseline (Day 1) to Month 6
- Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Retinal ThicknessTime frame: Baseline (Day 1) to Month 6
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco - Mission Bay /ID# 235717
San Francisco, California
Cincinnati Eye Institute- Edgewood /ID# 236713
Edgewood, Kentucky
Duke Eye Center /ID# 235715
Durham, North Carolina
Retina Foundation of the Southwest /ID# 235199
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.